PYC Therapeutics (PYC) Q3 2025 earnings summary

Executive summary

• Focus on developing disease-modifying RNA therapies for severe, single-gene diseases with high unmet need, including Polycystic Kidney Disease (PKD), Phelan-McDermid Syndrome (PMS), and two ophthalmology indications.

• Advanced third drug program into human trials for PKD, with three clinical-stage assets addressing root causes of severe diseases and human safety and efficacy data expected across four indications in the next 24 months.

• Multiple near-term human efficacy readouts expected, starting with Phase 1/2 data for Retinitis Pigmentosa in May 2025.

• Emphasis on targeting root causes of disease, aiming for not just halting but potentially reversing disease phenotypes, especially in PKD and PMS.

• Transitioning to a multi-asset, late clinical-stage company in 2H 2025, on track to become a commercial-stage drug developer within 48 months.

Financial highlights

• PKD represents a $15B+ annual market; PMS estimated at $4B in the US alone, with potential for $5B–$10B globally.

• Ophthalmology programs (RP11, ADOA) each target $1B–$3B annual markets.

• Cash on hand at 31 March 2025 was $138.1 million, with an additional $37.1 million received post-quarter from a $146 million Entitlement Offer.

• Net cash used in operating activities for the quarter was $(16.9) million; net cash from financing activities was $105.9 million.

• Estimated quarters of funding available is 8.16, with total available funding of $138.1 million.

Outlook and guidance

• All three clinical-stage programs to deliver human efficacy data within the next 12 months; all four pipeline assets expected to deliver human efficacy data within 24 months.

• Funded into calendar year 2027, supporting multiple clinical data readouts.

• PKD program to present safety data at a nephrology conference next month; full 12-month efficacy data expected by Q4 next year.

• Preparation underway for a potentially registrational trial in Retinitis Pigmentosa in 2025.

• PMS program to release pivotal non-human primate data next month, with clinical development targeted for the second half of next year.